ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2308건의 자료가 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1573 | Withdrawn | DAS181 for STOP COVID-19 | COVID-19 | Drug: DAS181 Drug: Placebo Drug: DAS181 |
Phase 3 | Ansun Biopharma, Inc. | INDUSTRY | 0 | All | 18 Years | Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milano, Italy A.O.U Policlinico Di Modena, Modena, Italy |
| 1572 | Withdrawn | Dasatinib for the Treatment of Moderate and Severe COVID-19 | Symptomatic COVID-19 Infection Laboratory-Confirmed | Drug: Dasatinib Anhydrous Drug: Placebo Administration |
Phase 2 | University of Southern California, National Cancer Institute (NCI) | OTHER | 0 | All | 18 Years | USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States |
| 1571 | Active, not recruiting | Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial | COVID-19 | Drug: Decitabine Other: Placebo Saline |
Phase 2 | Johns Hopkins University | OTHER | 33 | All | 18 Years | Johns Hopkins University, Baltimore, Maryland, United States |
| 1570 | Completed | Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19. | COVID19 | Drug: Defibrotide Drug: Placebo |
Phase 2 | Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia | OTHER | 156 | All | 18 Years | Hospital General Universitario Santa Lucia, Cartagena, Murcia, Spain Hospital Clinico y Provincial de Barcelona, Barcelona, Spain Virgen de la Arrixaca University Clinical Hospital, Murcia, Spain Hospital General Universitario Morales Meseguer, Murcia, Spain Hospital General Universitario Reina Sofia, Murcia, Spain Hospital Universitario Salamanca, Salamanca, Spain |
| 1569 | Recruiting | Defibrotide for the Treatment of Severe COVID-19 | Covid19 | Drug: Defibrotide | Phase 2 | Brigham and Women's Hospital, Jazz Pharmaceuticals | OTHER | 42 | All | 18 Years ~ 100 Years | Brigham and Women's Hospital, Boston, Massachusetts, United States |
| 1568 | Completed | Defibrotide in COVID-19 Pneumonia | Patients With COVID-19 Pneumonia Will Allow to Detect an Absolute Reduction in the Rate of Respiratory-failure | Drug: Defibrotide Injection | Phase 2 | IRCCS San Raffaele | OTHER | 50 | All | 18 Years | Ospedale San Raffaele, Milano, Lombardia, Italy |
| 1567 | Recruiting | DEFINE - Evaluating Therapies for COVID-19 | COVID-19 | Drug: Nafamostat Mesilate Drug: TD139 Other: Standard care Biological: Allogeneic SARS-CoV-2 VSTs |
Phase 2 | University of Edinburgh, University of Oxford, Latus Therapeutics, Scottish National Blood Transfusion Service (SNBTS) | OTHER | 200 | All | 16 Years | NHS Lothian, Edinburgh, United Kingdom |
